Share chart Acceleron Pharma Inc.
Extended chart
Simple chart
About
Acceleron Pharma Inc., биофармацевтическая компания, специализируется на открытии, разработке и коммерциализации терапевтических средств для лечения серьезных и редких заболеваний. Он предлагает люспатерсепт-амт для лечения анемии у взрослых пациентов с бета-талассемией под названием REBLOZYL.
More details| P/S | 144.77 |
|---|---|
| P/BV | 6.94 |
| EV/EBITDA | 0.3787 |
| EBITDA | -0.0553 |
| Цена ао | 178.75 |
| Сайт | http://www.acceleronpharma.com |
| Число акций ао | 56 млн |
| Выручка | 0.0278 |
| Див.доход ао | 0 |
| ISIN | US00434H1086 |
| Change price per day: | 0% (178.75) |
|---|---|
| Change price per week: | 0% (178.75) |
| Change price per month: | 0% (178.75) |
| Change price per 3 month: | 0% (178.75) |
| Change price per half year: | 0% (178.75) |
| Change price per year: | 0% (178.75) |
| Change price per 3 year: | 0% (178.75) |
| Change price per 5 year: | +280.89% (46.93) |
| Change price per year to date: | 0% (178.75) |
All parameters ⇨
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Transaction date | Date of disclosure | Insider | Type | Price | Volume | Quantity | Share before, % | Share after, % | Document |
|---|---|---|---|---|---|---|---|---|---|
| 27.09.2021 | 27.09.2021 | KANGO SUJAY EVP, Chief Commercial Officer |
Sale | 175 | 875 000 | 5000 | 0 | -0.01 | link |
| 27.09.2021 | 27.09.2021 | KANGO SUJAY EVP, Chief Commercial Officer |
Purchase | 40.61 | 203 050 | 5000 | 0 | 0.01 | link |
| 24.09.2021 | 24.09.2021 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Sale | 160.38 | 861 241 | 5370 | 0 | -0.01 | link |
| 24.09.2021 | 24.09.2021 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Purchase | 40.64 | 218 237 | 5370 | 0 | 0.01 | link |
| 23.09.2021 | 24.09.2021 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Sale | 160.31 | 3 146 880 | 19630 | 0 | -0.03 | link |
| 23.09.2021 | 24.09.2021 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Purchase | 39.67 | 778 722 | 19630 | 0 | 0.03 | link |
| 02.07.2021 | 02.07.2021 | Dable Habib J CEO and President |
Sale | 126.97 | 5 356 360 | 42186 | 0 | -0.08 | link |
| 02.07.2021 | 02.07.2021 | Dable Habib J CEO and President |
Purchase | 35.04 | 1 478 200 | 42186 | 0 | 0.08 | link |
| 01.07.2021 | 02.07.2021 | Dable Habib J CEO and President |
Sale | 126.73 | 7 326 770 | 57814 | 0 | -0.11 | link |
| 01.07.2021 | 02.07.2021 | Dable Habib J CEO and President |
Purchase | 35.04 | 2 025 800 | 57814 | 0 | 0.11 | link |
| 11.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Sale | 125 | 387 500 | 3100 | 0 | -0.01 | link |
| 10.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Sale | 125.12 | 62 560 | 500 | 0 | 0 | link |
| 09.12.2020 | 11.12.2020 | MCLAUGHLIN KEVIN F SVP, CFO and Treasurer |
Sale | 125.03 | 484 116 | 3872 | 0 | -0.01 | link |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Habib J. Dable | CEO, Pres & Director | 1.26M | 1969 (55 years) |
| Mr. Kevin F. McLaughlin | Sr. VP, CFO & Treasurer | 712.08k | 1956 (68 years) |
| Mr. Adam M. Veness Esq. | Sr. VP, Gen. Counsel & Sec. | 690.62k | 1986 (38 years) |
| Mr. Sujay R. Kango | Exec. VP & Chief Commercial Officer | 702.16k | 1964 (60 years) |
| Dr. Jay T. Backstrom M.D., M.P.H. | Exec. VP of R&D | 850k | 1955 (69 years) |
| Dr. Thomas P. Maniatis | Co-Founder, Member of Scientific Advisory Board & Director Emeritus | N/A | 1943 (81 year) |
| Dr. Mark Ptashne | Co-Founder and Member of Scientific Advisory Board | N/A | |
| Ms. Lisa Wyman | Sr. VP of Technical Operations | N/A | |
| Dr. Ravindra Kumar | Chief Scientific Officer & Sr. VP | N/A | 1960 (64 years) |
| Mr. Todd James IRC | Sr. VP of Corp. Affairs & Investor Relations | N/A | |
Address: United States, Cambridge, MA , 128 Sidney Street - open in Google maps, open in Yandex maps
Website: http://www.acceleronpharma.com
Website: http://www.acceleronpharma.com
